Cargando…
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630263/ https://www.ncbi.nlm.nih.gov/pubmed/37817017 http://dx.doi.org/10.1007/s40120-023-00554-w |
| _version_ | 1785146012776529920 |
|---|---|
| author | Aldred, Jason Freire-Alvarez, Eric Amelin, Alexander V. Antonini, Angelo Bergmans, Bruno Bergquist, Filip Bouchard, Manon Budur, Kumar Carroll, Camille Chaudhuri, K. Ray Criswell, Susan R. Danielsen, Erik H. Gandor, Florin Jia, Jia Kimber, Thomas E. Mochizuki, Hideki Robieson, Weining Z. Spiegel, Amy M. Standaert, David G. Talapala, Saritha Facheris, Maurizio F. Fung, Victor S. C. |
| author_facet | Aldred, Jason Freire-Alvarez, Eric Amelin, Alexander V. Antonini, Angelo Bergmans, Bruno Bergquist, Filip Bouchard, Manon Budur, Kumar Carroll, Camille Chaudhuri, K. Ray Criswell, Susan R. Danielsen, Erik H. Gandor, Florin Jia, Jia Kimber, Thomas E. Mochizuki, Hideki Robieson, Weining Z. Spiegel, Amy M. Standaert, David G. Talapala, Saritha Facheris, Maurizio F. Fung, Victor S. C. |
| author_sort | Aldred, Jason |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10630263 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106302632023-11-14 Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study Aldred, Jason Freire-Alvarez, Eric Amelin, Alexander V. Antonini, Angelo Bergmans, Bruno Bergquist, Filip Bouchard, Manon Budur, Kumar Carroll, Camille Chaudhuri, K. Ray Criswell, Susan R. Danielsen, Erik H. Gandor, Florin Jia, Jia Kimber, Thomas E. Mochizuki, Hideki Robieson, Weining Z. Spiegel, Amy M. Standaert, David G. Talapala, Saritha Facheris, Maurizio F. Fung, Victor S. C. Neurol Ther Correction Springer Healthcare 2023-10-10 /pmc/articles/PMC10630263/ /pubmed/37817017 http://dx.doi.org/10.1007/s40120-023-00554-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Aldred, Jason Freire-Alvarez, Eric Amelin, Alexander V. Antonini, Angelo Bergmans, Bruno Bergquist, Filip Bouchard, Manon Budur, Kumar Carroll, Camille Chaudhuri, K. Ray Criswell, Susan R. Danielsen, Erik H. Gandor, Florin Jia, Jia Kimber, Thomas E. Mochizuki, Hideki Robieson, Weining Z. Spiegel, Amy M. Standaert, David G. Talapala, Saritha Facheris, Maurizio F. Fung, Victor S. C. Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study |
| title | Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study |
| title_full | Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study |
| title_fullStr | Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study |
| title_full_unstemmed | Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study |
| title_short | Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study |
| title_sort | correction: continuous subcutaneous foslevodopa/foscarbidopa in parkinson’s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630263/ https://www.ncbi.nlm.nih.gov/pubmed/37817017 http://dx.doi.org/10.1007/s40120-023-00554-w |
| work_keys_str_mv | AT aldredjason correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT freirealvarezeric correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT amelinalexanderv correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT antoniniangelo correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT bergmansbruno correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT bergquistfilip correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT bouchardmanon correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT budurkumar correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT carrollcamille correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT chaudhurikray correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT criswellsusanr correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT danielsenerikh correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT gandorflorin correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT jiajia correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT kimberthomase correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT mochizukihideki correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT robiesonweiningz correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT spiegelamym correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT standaertdavidg correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT talapalasaritha correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT facherismauriziof correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study AT fungvictorsc correctioncontinuoussubcutaneousfoslevodopafoscarbidopainparkinsonsdiseasesafetyandefficacyresultsfroma12monthsinglearmopenlabelphase3study |